Strategy shares slip after wider-than-expected loss on Bitcoin decline
Strategy Incorporated (NASDAQ:MSTR) shares fell roughly 2% in Wednesday morning trading after the Bi…
proactiveinvestors.com
CRSP(CRSP)
CRSP
Next earnings: Aug 3, 2026
Signal
Bullish Setup2↑
PRICE
Prev Close
52.38
Open
52.90
Day Range52.69 – 54.12
52.69
54.12
52W Range33.03 – 78.48
33.03
78.48
46% of range
VOLUME & SIZE
Avg Volume
1.9M
FUNDAMENTALS
P/E Ratio
-8.1x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.44
Market-like
Performance
1D
-2.24%5D
+2.07%1M
+6.57%3M
+14.17%6M↓
-8.09%YTD
-0.11%1Y↑
+39.23%Best: 1Y (+39.23%)Worst: 6M (-8.09%)
Quick Read
Trend—Insufficient MA data
Momentum
BEARISH
revenue -89% YoY · thin -4172% gross marginValuation
FAIR
P/E not availableHealth
MODERATE
CR 18.0 · FCF negativeLean Bearish
Key MetricsTTM
Market Cap$5.05B
Revenue TTM$4.10M
Net Income TTM-$568.53M
Free Cash Flow-$401.18M
Gross Margin-4171.7%
Net Margin-13856.5%
Operating Margin-13408.3%
Return on Equity-30.9%
Return on Assets-20.9%
Debt / Equity0.43
Current Ratio17.96
EPS TTM$-5.92
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
2 strong1 watch3 concern
40/100Liquidity
17.96Strong
Leverage
0.43Strong
Coverage
0.0xConcern
ROE
-30.9%Concern
ROIC
-21.1%Concern
Cash
$355MWatch
ANALYST COVERAGE30 analysts
BUY
▲ +37.2%upside to target
L $33.00
Med $74.00consensus
H $82.00Stock Health
Composite Score
4 of 5 signals bullish
8/10
Technicals
●
✓RSI RangeRSI 53 — Bullish momentum
Volume
●
✓Volume FlowAccumulation — institutional buying
Fundamentals
●
✗Last EarningsMissed estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 17.96 — healthy liquidity
Upcoming Events
EEarnings Report · Before OpenMay 7, 2026
Tomorrow
DEx-Dividend DateAug 4, 2026
In 90 days
PDividend PaymentSep 1, 2026
In 118 days
FinancialsFull statements →
Technicals
Technical SetupBULLISH
Technicals →Trend
▲ RallyDeath Cross · 50D trails 200D by 7.2%
+3.1% vs SMA 50 · -4.4% vs SMA 200
Momentum
RSI52.6Neutral territory
MACD+0.23Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$78.48+45.5%
Current
$53.95
EMA 200
$53.57-0.7%
EMA 50
$52.49-2.7%
52W Low
$33.03-38.8%
52-Week RangeMid-range
$33.0346th %ile$78.48
Squeeze SetupVolume-based
Elevated Squeeze SetupStrong accumulation on above-average volume. Buyers are absorbing supply aggressively — any positive catalyst could trigger a rapid covering move.
20-Day Money Flow
Acc days:10
Dist days:2
Edge:+8 acc
Volume Context
Avg Vol (50D)3.2M
Recent Vol (5D)
5.6M+75%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 19 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $7.1M $3.8M–$21.9M | — | -$6.21 | — | ±8% | High19 |
FY2026(current) | $48.0M $2.7M–$204.6M | ▲ +580.5% | -$4.85 | — | ±42% | High19 |
FY2027 | $149.3M $2.1M–$528.2M | ▲ +211.2% | -$3.72 | — | ±50% | High16 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryCRSP
Last 8Q
+8.1%avg beat
Beat 5 of 8 quartersMissed 3↑ Estimates rising+12%
Q2'24
-9%
Q3'24
+24%
Q4'24
+62%
Q1'25
-24%
Q2'25
+12%
Q3'25
+7%
Q4'25
-19%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightAnalyst Activity
All ratings →No recent activity
Cantor FitzgeraldOverweight → Neutral
Oct 17
DOWNGRADE
CitigroupNeutral → Buy
Aug 17
UPGRADE
Insider Activity
SEC Filings →0 Buys/6 SellsNet Selling
Kasinger James R.General Counse…
$149K
Mar 23
SELL
Kulkarni SamarthCEO
$469K
Mar 23
SELL
Prasad RajuCFO
$173K
Mar 23
SELL
Patel NaimishChief Medical …
$152K
Mar 16
SELL
Prasad RajuCFO
$282K
Mar 16
SELL
Prasad RajuCFO
$194K
Mar 16
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
Sumitomo Mitsui Trust Holdings, Inc.
1.9M▼2
UBS Group AG
1.8M▼3
Bank of New York Mellon Corp
311K▲4
Nuveen, LLC
191K▲5
Pictet Asset Management Holding SA
154K▼6
Versant Venture Management, LLC
149K—7
Reynders McVeigh Capital Management, LLC
123K▲8
CONGRESS ASSET MANAGEMENT CO /MA
108K▲News & Activity
CRSP News
20 articles · 4h ago
Best Income Stocks to Buy for May 6th
zacks.com
BRIGHT and LanzaTech launch new partnership to accelerate carbon-to-value biotechnology in Europe
globenewswire.com
Madison Square Garden Sports Group: Ride The Momentum
seekingalpha.com
Super Micro Computer: Sell The Rip While You Can
seekingalpha.com
Match Group: Impressive Profit Growth, But What Matters Is Payer Expansion
seekingalpha.com
CN Presents the 2025 Safe Handling Award to 194 Rail Shippers
globenewswire.com
Atos SE Announces the Offering of Senior Secured Fixed Rate Notes Due 2031 and Senior Secured Floating Rate Notes Due 2031, and Entry into New Revolving Credit Facility
globenewswire.com
EdgeMode Appoints Capital Markets Specialist Simon Kiero-Watson to Board of Directors
globenewswire.com
International Markets and F5 (FFIV): A Deep Dive for Investors
zacks.com
Gear Up for Reinsurance Group (RGA) Q1 Earnings: Wall Street Estimates for Key Metrics
zacks.com
Celestica, Inc. (CLS) Soars to 52-Week High, Time to Cash Out?
zacks.com
Unveiling Fox (FOXA) Q3 Outlook: Wall Street Estimates for Key Metrics
zacks.com
Mistras Group Inc (MG) Hit a 52 Week High, Can the Run Continue?
zacks.com
V2X, Inc. (VVX) Soars to 52-Week High, Time to Cash Out?
zacks.com
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
zacks.com
Crescent Energy Company (CRGY) Hits Fresh High: Is There Still Room to Run?
zacks.com
Countdown to Shift4 Payments (FOUR) Q1 Earnings: Wall Street Forecasts for Key Metrics
zacks.com
Flex Ltd. (FLEX) Hits Fresh High: Is There Still Room to Run?
zacks.com
Gear Up for Outfront Media (OUT) Q1 Earnings: Wall Street Estimates for Key Metrics
zacks.com
About
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
Sector
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
Samarth Kulkarni
Country
Switzerland
Website
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
CRSP◀ | $53.88 | -2.24% | $5.1B | — | -8997.1% | -1656977.2% | 1500 |
| $68.82 | -0.30% | $13.3B | — | +12626.1% | -14525.8% | 1500 | |
| $91.34 | -1.81% | $11.7B | — | +3288.2% | -4239.0% | 1500 | |
| $536.00 | -3.12% | $11.5B | — | +43205.3% | -3008.0% | 1500 | |
| $226.34 | -0.29% | $11.4B | — | +6554.5% | -2868.8% | 1500 | |
| $76.26 | -1.91% | $10.5B | 51.9 | +2325815.3% | -19.7% | 1500 | |
| $176.76 | -3.34% | $10.3B | 28.0 | +1871.5% | 680.1% | 1500 | |
| Sector avg | — | -1.86% | — | 39.9 | +340623.4% | -240136.9% | 1500 |